Intriguingly, phenotypic analyses showed all three B3GNT2 mutants as significantly enhancing the migratory potential of colon adenocarcinoma cells (Fig. 5), indicating a gain of oncogenic function likely resulting from dominant negative activities of the mutant enzymes against wild-type B3GNT2 and/or other glycosyltransferases. This evidence concerns the gene B3GNT2 and colon adenocarcinoma.